Philanthropy, psychedelics and effective altruism

Psychedelic drugs are having a moment in the sun. They have great potential, we’re learning, as a treatment for a variety of mental illnesses, including post-traumatic stress disorder and depression. They are also attracting interest as a gateway to meaningful experiences that, advocates say, should be available to all.

Philanthropists are taking note. More donors — though not nearly enough — are stepping up to support both research into the medical benefits of these days and advocacy on their behalf.

Here’s why psychedelics present an untapped opportunity for philanthropy.

The latest on psychedelics as therapy: Last month in London, Imperial College opened the world’s first formal center for psychedelics research, which will seek to developing psilocybin therapy into a licensed treatment for depression and investigate its potential for treating other conditions. Dr. Robin Carhart-Harris, a prominent researcher who is leading the effort, says: “This new Centre represents a watershed moment for psychedelic science; symbolic of its now mainstream recognition.” Five founding donors, including the best-selling author, podcaster and investor Tim Ferriss, have committed a total of £3 million ($3.9 million US) to fund the center.